Nicholas Valerie
Nicholas Valerie
Karolinska Institutet; Science for Life Laboratory
Verified email at scilifelab.se - Homepage
Title
Cited by
Cited by
Year
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
SE Golding, E Rosenberg, N Valerie, I Hussaini, M Frigerio, XF Cockcroft, ...
Molecular cancer therapeutics, 1535-7163. MCT-09-0519, 2009
2622009
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation
L Biddlestone-Thorpe, M Sajjad, E Rosenberg, JM Beckta, NCK Valerie, ...
Clinical Cancer Research 19 (12), 3189-3200, 2013
1312013
Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2
M Carter, AS Jemth, A Hagenkort, BDG Page, R Gustafsson, JJ Griese, ...
Nature communications 6 (1), 1-10, 2015
692015
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
N Herold, SG Rudd, L Ljungblad, K Sanjiv, IH Myrberg, CBJ Paulin, ...
Nature medicine 23 (2), 256, 2017
582017
Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells
NCK Valerie, B Dziegielewska, AS Hosing, E Augustin, LS Gray, ...
Biochemical pharmacology 85 (7), 888-897, 2013
552013
Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation
NCK Valerie, EV Casarez, JO DaSilva, ME Dunlap-Brown, SJ Parsons, ...
Cancer research 71 (21), 6817-6826, 2011
472011
NUDT15 hydrolyzes 6-thio-deoxyGTP to mediate the anticancer efficacy of 6-thioguanine
NCK Valerie, A Hagenkort, BDG Page, G Masuyer, D Rehling, M Carter, ...
Cancer research 76 (18), 5501-5511, 2016
442016
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination
SM Dever, SE Golding, E Rosenberg, BR Adams, MO Idowu, JM Quillin, ...
Aging (Albany NY) 3 (5), 515, 2011
392011
Pathways controlling dNTP pools to maintain genome stability
SG Rudd, NCK Valerie, T Helleday
DNA Repair 44, 193-204, 2016
312016
PP6 regulatory subunit R1 is bidentate anchor for targeting protein phosphatase-6 to DNA-dependent protein kinase
AS Hosing, NCK Valerie, J Dziegielewski, DL Brautigan, JM Larner
Journal of Biological Chemistry 287 (12), 9230-9239, 2012
302012
Discovery of the first potent and selective inhibitors of human dCTP pyrophosphatase 1
S Llona-Minguez, A Hoglund, SA Jacques, L Johansson, ...
Journal of medicinal chemistry 59 (3), 1140-1148, 2016
242016
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
BDG Page, NCK Valerie, RHG Wright, O Wallner, R Isaksson, M Carter, ...
Nature communications 9 (1), 1-14, 2018
142018
Piperazin-1-ylpyridazine derivatives are a novel class of human dCTP pyrophosphatase 1 inhibitors
S Llona-Minguez, A Hoglund, A Ghassemian, M Desroses, ...
Journal of medicinal chemistry 60 (10), 4279-4292, 2017
112017
Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
J Karlin, J Allen, SF Ahmad, G Hughes, V Sheridan, R Odedra, ...
Molecular cancer therapeutics 17 (8), 1637-1647, 2018
82018
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
BDG Page, NCK Valerie, RHG Wright, O Wallner, R Isaksson, M Carter, ...
Nature communications 10 (1), 1-1, 2019
12019
Abstract LB-262: Targeting T-type calcium channels induces the extrinsic apoptotic pathway and sensitizes glioblastoma cancer cells to radio-and chemotherapy
J Dziegielewski, NCK Valerie, B Dziegielewska, AS Hosing, LS Gray, ...
Cancer Research 72 (8 Supplement), LB-262-LB-262, 2012
12012
Roles of NUDT5 and NUDT15 beyond oxidized nucleotide sanitation and their potential as therapeutic targets
NCK Valerie
Inst för medicinsk biokemi och biofysik/Dept of Medical Biochemistry and …, 2018
2018
Abstract A239: T-type calcium channels as a novel molecular target for tumor therapy.
B Dziegielewska, NCK Valerie, AS Hosing, JM Larner, DL Brautigan, ...
Molecular Cancer Therapeutics 12 (11 Supplement), A239-A239, 2013
2013
Neurotensin receptor antagonist, SR48692, sensitizes prostate cancer cells to radiation in vitro and in vivo
EV Casarez, JO DaSilva, NCK Valerie, S Anaganti, ME Dunlap-Brown, ...
Cancer Research 71 (8 Supplement), 2505-2505, 2011
2011
The system can't perform the operation now. Try again later.
Articles 1–19